Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome

Lupus. 1998;7(7):495-7. doi: 10.1191/096120398678920442.

Abstract

Severe pulmonary hypertension (PHT) occurring in patients with systemic lupus erythematosus (SLE) is uncommon. Different modalities have been tried in the treatment for this condition but have not been effective because of progressive increase of pulmonary resistance over time. Our patient with SLE and PHT with antiphospholipid syndrome (APS), a condition which has previously never been described, responded rapidly to combination treatment with immunosuppression, anticoagulation and vasodilator therapy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anticoagulants / therapeutic use*
  • Antiphospholipid Syndrome / drug therapy*
  • Antiphospholipid Syndrome / etiology
  • Cyclophosphamide / therapeutic use
  • Diltiazem / therapeutic use*
  • Female
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / etiology
  • Immunosuppressive Agents / therapeutic use*
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / drug therapy*
  • Prednisone / therapeutic use
  • Vasodilator Agents / therapeutic use*
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Immunosuppressive Agents
  • Vasodilator Agents
  • Warfarin
  • Cyclophosphamide
  • Diltiazem
  • Prednisone